Sign in Subscribe
Pharmaceutical industry

ID Biomedical Corporation Secures Long-Term Vaccine Distribution Deals

Strategic Insights

— 1 min read

ID Biomedical Corporation has formed partnerships with three prominent distributors, Henry Schein, AmerisourceBergen Corporation's Specialty Group, and McKesson Corporation, to market and distribute its Fluviral influenza vaccine in the U.S. The agreements, set to begin as early as next year, are contingent upon U.S. Food and Drug Administration (FDA) clearance and are expected to cover at least eight influenza seasons through 2014/2015. The total value of the purchases is estimated to be approximately $2.3 billion, with the potential to increase to $2.5 billion if Fluviral is approved on an accelerated basis for the 2005/06 and 2006/07 seasons.

Key Takeaways:

  • ID Biomedical Corporation has signed long-term marketing, distribution, and minimum purchase agreements with Henry Schein, AmerisourceBergen Corporation's Specialty Group, and McKesson Corporation.
  • The agreements are contingent upon U.S. FDA clearance and are expected to cover at least eight influenza seasons through 2014/2015.
  • The total value of the purchases is estimated to be approximately $2.3 billion, with the potential to increase to $2.5 billion if Fluviral is approved on an accelerated basis.
  • ID Biomedical's production capacity is expected to increase from 22 million doses in 2005 to 50 million doses by 2007.
  • The company has commitments to supply the Canadian market with up to 12 million doses annually through 2011.
  • ID Biomedical operates in research, development, manufacturing, sales, and marketing from its facilities in Canada and the United States.

Statistics:

  • Estimated total value of purchases: $2.3 billion (potential increase to $2.5 billion)
  • Total number of doses to be purchased under the agreements: at least eight influenza seasons (2006/2007 to 2014/2015)
  • ID Biomedical's production capacity in 2005: approximately 22 million doses
  • ID Biomedical's production capacity by 2007: approximately 50 million doses
  • ID Biomedical's commitments to supply the Canadian market through 2011: up to 12 million doses annually

Sources:

  • [1] ID Biomedical Corporation (2005) Press release: ID Biomedical Corporation Signs Long-Term Agreements with Henry Schein, Inc. and AmerisourceBergen Corporation's Specialty Group and McKesson Corporation for Distribution and Marketing of Fluviral.
  • [2] Health & Medicine Week editors (2005, Copyright 2005, Health & Medicine Week via NewsRx.com & NewsRx.net) Article: ID Biomedical Corporation Signs Long-Term Agreements with Distributors.

Read more